Neuroimmunology Market Revenue to Attain USD 91.88 Bn by 2035

Neuroimmunology Market Revenue and Trends 2026 to 2035

The global neuroimmunology market revenue was valued at USD 37.80 billion in 2025 and is expected to attain around USD 91.88 billion by 2035, growing at a CAGR of 8.90% during forecast period. The market is driven by an increase in the number of autoimmune neurological disorders, such as multiple sclerosis, neuromyelitis optica, and myasthenia gravis, and growing research initiatives in neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.

Neurology and Immunology Intersection Point

The neuroimmunology market comprises diagnostic tests and therapies that are employed to treat disorders caused by immune response against the body’s nervous system, such as autoimmune encephalitis, MOG antibody disease, and acute disseminated encephalomyelitis. This market entails the testing tools and technologies, including cell-based, ELISA, and immunofluorescence-based antibody detection tests. It also involves cerebrospinal fluid testing for oligoclonal bands and IgG index, flow cytometry, and MRI imaging methods.

There are some products for therapy, such as monoclonal antibodies (rituximab, ocrelizumab, ofatumumab), and compliment inhibitors (eculizumab), IL-6 receptor blockers, and IVIg. This market has been adopted in neurological departments at hospitals, immunological centers, diagnostic laboratories, and the drug manufacturing sector. In addition to the classic autoimmune diseases, there is now interest in the role of the immune response in the neuroinflammatory aspects of Alzheimer’s and Parkinson’s disease.

Automated NfL Blood Test for Neurological Disorders Monitoring

The latest trend in the market is the incorporation of fully automated blood tests to detect the level of neurofilament light chain (NfL), which allows the quantification of axonal damage in patients suffering from various neurological diseases. This new technique is useful in diagnosing multiple sclerosis, Alzheimer’s disease, and traumatic brain injury. In 2026, Fujirebio Europe N.V. acquired the CE Certificate of its Lumipulse G NfL Blood assay under IVDR legislation. It is a fully automated chemiluminescent enzyme immunoassay designed to quantitatively measure NfL in serum and plasma samples.

Implementation of Reimbursement Pathways for Neuroimmune Biomarker Testing

The neuroimmunology market is witnessing the rapid adoption of reimbursement policies for biomarker testing related to neurological conditions, enabling the usage of these tests in clinical practice, which until now was confined to experimental settings only. This trend towards reimbursement is prompting the increased usage of blood and cerebrospinal fluid neuroimmunology biomarker panels among clinicians treating their patients with neurological disorders. In 2025, EmblemHealth and ConnectiCare introduced a new reimbursement policy for biomarker testing for multiple sclerosis and related neurologic diseases under their Lab Benefit Management Plan.

Government Investment in Neuroimmunology Research Infrastructure

Governments across the world have started large funding initiatives to support research in neuroimmunology that recognizes the importance of the immune system in neurological disorders like Alzheimer’s disease and Parkinson’s disease. In 2026, the Government of Canada announced a USD 14.5 million funding grant under the Innovation Fund by the Canada Foundation for Innovation. This grant is intended to support neuroimmunology research initiatives at The Neuro (Montreal Neurological Institute-Hospital), which includes the McGill Platform for Neuroinflammation Research and Imaging Parkinson’s Disease across scales.

Crowdfunding Campaign Helps ALA Diagnostics Raise Funds for Blood Diagnostic Tests

Through crowdfunding campaigns in 2025, Spanish biotechnology company ALA Diagnostics managed to raise more than USD 992,000. These funds will be used to develop a non-invasive blood test for multiple sclerosis, which employs a patented biomarker proven in 598 patients with high sensitivity and specificity above 90 percent.

Market Segmentation Overview

• By disease type, the multiple sclerosis segment led the neuroimmunology market with 36% share in 2025, since it requires consistent diagnosis through tests to measure the presence of the disease using MRI, cerebrospinal fluid analysis, and blood biomarkers, and due to its high prevalence across the world.
• By disease type, the neuroinflammatory disorders segment is expected to expand at the highest CAGR of 12.5% during the forecast period, because new findings have proved that neuroinflammation is an integral part of some of the major neurodegenerative diseases, and biomarkers such as NfL and GFAP allow the monitoring of neuroinflammation.
• By treatment type, the monoclonal antibodies segment dominated the market with 30% share in 2025 and is expected to grow at the fastest CAGR of 12.8% from 2026 to 2035, due to its effectiveness in relapsing remitting multiple sclerosis, neuromyelitis optica, and myasthenia gravis, and its efficacy surpasses that of first-line immunomodulators.
• By treatment type, the immunomodulators segment held the second-largest market share of 24% in 2025, because the therapy for multiple sclerosis with both orally and parentally administered immunomodulators has traditionally been the standard therapy due to its ease of administration and lower prices than monoclonal antibodies.
• By mechanism of action, the B-cell targeting therapies segment led the market with 28% share in 2025, due to the excellent efficacy shown by CD20-positive B-cell depleting monoclonal antibodies such as rituximab, ocrelizumab, ofatumumab, and inebilizumab for reducing relapse and disability progression.
• By mechanism of action, the complement inhibition segment is expected to expand at the highest CAGR of 14.5% during the forecast period, because of the success of eculizumab and ravulizumab in neuromyelitis optica. The newer drugs under development for neuroimmune diseases, such as Guillain-Barré syndrome, will boost this segment’s growth due to their biomarker-based treatment algorithms that focus on the involvement of the complement system in disease pathology.

Regional Analysis

North America led the neuroimmunology market with 39% share in 2025, since this region has a high prevalence of multiple sclerosis and other neuroimmune conditions, an established infrastructure of neurology specialty centers and laboratories, and coverage of biological treatment and advanced diagnostic tests by insurance companies. The U.S. dominated the market in North America owing to the presence of prominent pharmaceutical companies that develop monoclonal antibodies and complement inhibitors, and the high popularity of blood-based biomarker tests and MRI among healthcare facilities. Canada witnessed notable market growth due to the high prevalence of multiple sclerosis, a universal healthcare system that offers free services, including advanced diagnostics and biological therapies to all patients.

Asia-Pacific is expected to grow at the fastest CAGR of 13.5% from 2026 to 2035, owing to its huge population, improved awareness about neuroimmunological conditions among healthcare professionals, and expansion of healthcare facilities. China led the market in Asia Pacific due to significant spending on healthcare, government efforts to develop standardized diagnosis procedures for diseases like multiple sclerosis and neuromyelitis optica, and the increasing adoption of monoclonal antibody therapies and autoantibody test kits. Japan is a significant contributor to the market because of its advanced healthcare delivery system, higher prevalence rate of neuroimmunological disorders, and good research infrastructure.

Neuroimmunology Market Coverage

Top Companies in the Neuroimmunology Market

Biogen Inc., F. Hoffmann-La Roche Ltd., Novartis AG, and Sanofi S.A. are some of the key players that provide drugs for multiple sclerosis and neuromyelitis optica. Bristol Myers Squibb, Merck KGaA, and Teva Pharmaceutical Industries Ltd. offer multiple sclerosis disease-modifying drugs such as Zeposia, Mavenclad, and Copaxone. Alexion Pharmaceuticals and UCB Pharma target rare neuroimmunological diseases. Alexion Pharmaceuticals provides Soliris and Ultomiris for neuromyelitis optica and myasthenia gravis, while UCB Pharma provides rozanolixizumab for generalized myasthenia gravis. AbbVie Inc., Eli Lilly and Company, Johnson & Johnson, and Takeda Pharmaceutical Company Limited focus on BTK inhibitors and anti-IL-6 drugs.

Segments Covered in This Report

By Disease Type

• Multiple Sclerosis
• Neuromyelitis Optica Spectrum Disorder
• Myasthenia Gravis
• Autoimmune Encephalitis
• Guillain-Barré Syndrome
• Chronic Inflammatory Demyelinating Polyneuropathy
• Neuroinflammatory Disorders
• Other Neuroimmune Disorders

By Treatment Type

• Immunomodulators
• Immunosuppressants
• Monoclonal Antibodies
• Corticosteroids
• Intravenous Immunoglobulin
• Plasma Exchange
• Cell-based Therapies
• Other Biologic Therapies

By Mechanism of Action

• B-cell Targeting Therapies
• T-cell Modulation
• Complement Inhibition
• Cytokine Inhibition
• Neuroprotection
• Anti-inflammatory Therapy

By Route of Administration

• Oral
• Injectable
• Intravenous (IV)
• Subcutaneous

By End-user

• Hospitals
• Specialty Neurology Clinics
• Research & Academic Institutes
• Homecare Settings
• Rehabilitation Centers

By Region

• North America
• Latin America
• Europe
• Asia-pacific
• Middle and East Africa

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/8446

You can place an order or ask any questions. Please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344